Hangzhou Alltest Biotech (688606)2025-01-20 09:50Financial Projections - The company expects to achieve an annual revenue of between 855 million to 870 million CNY in 2024, representing a year-on-year increase of 13.29% to 15.28% compared to 2023[3] - The projected net profit attributable to the parent company for 2024 is between 278 million to 298 million CNY, reflecting a year-on-year increase of 53.95% to 65.03%[3] - The estimated net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be between 221 million to 241 million CNY, indicating a year-on-year increase of 50.42% to 64.03%[3] - In 2023, the company achieved a revenue of 754.70 million CNY and a net profit of 180.58 million CNY[5] Operational Strategies - The company continues to focus on the POCT segment of the in vitro diagnostic industry, driving product and service innovation while deepening market expansion strategies[7] - The company has strengthened internal management to enhance operational efficiency and cost control, contributing to steady performance growth[7] Performance Forecast Validity - The financial data in the performance forecast has not been audited by a registered accountant and is based on preliminary calculations by the company's finance department[4] - As of the announcement date, the company has not identified any significant uncertainties that could affect the accuracy of the performance forecast[8] - The projected performance is preliminary and the final audited financial data will be disclosed in the official 2024 annual report[9] - Investors are advised to pay attention to investment risks related to the preliminary nature of the performance forecast[9]